WHO ICTRP trial
Expression of MYC gene in multiple myeloma with 1q21 amplification treated with…
ChiCTR2100046294 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100046294 |
|---|---|
| Public title | Expression of MYC gene in multiple myeloma with 1q21 amplification treated with bortezomib-based regimen and its clinical significance |
| Scientific title | Expression of MYC gene in multiple myeloma with 1q21 amplification treated with bortezomib-based regimen and its clinical significance |
| Primary sponsor | Mianyang Central Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | 0 |
| Countries | China |
| Conditions | multiple myeloma |
| Interventions | According to the abnormal status of MYC gene, it was divided into rearrangement group, mutation group and no abnormality group. :Nil |
| Registration date | May 12, 2021 |
| Target size | According to the abnormal status of MYC gene, it was divided into rearrangement… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: